VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AFGDAmerican Financial Group, Inc.
$19.51$1.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAFGDFinancials

American Financial Group, Inc. (AFGD) Financials

22Y historyFree accessUpdated daily

Underwriting discipline remains a core driver of profitability, as evidenced by the 81.6% combined ratio reported in 2025Q4 despite volatile revenue growth that saw a 4.9% contraction in 2025Q1.

AFGD Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03
Revenue8.05B8.12B8.01B7.45B6.81B6.23B5.58B5.97B6.99B6.8B6.45B6.28B5.65B5.02B4.72B4.75B4.5B294.1M344.1M364.7M414.99B342.42B266.65B
Revenue Growth %0.31%1.34%7.49%9.43%9.36%11.62%-6.61%-14.52%2.76%5.41%2.76%11.11%12.61%6.4%-0.72%5.63%1429.07%-14.53%-5.65%-99.91%21.19%28.42%-
Medical Costs & Claims1.06B4.39B000000-161M-64M-46M134M-62M-74M404M363M378M463M549.9M463.8M477.65B519.9B447B
Medical Cost Ratio %13.18%54.06%0%0%0%0%0%0%-2.3%-0.94%-0.71%2.13%-1.1%-1.47%8.57%7.64%8.41%157.43%159.81%127.17%115.1%151.83%167.64%
Gross Profit5.14B3.73B8.01B7.45B6.81B6.39B5.58B5.97B7.15B6.87B6.5B6.14B5.71B5.09B4.31B4.39B4.12B-168.9M-205.8M-99.1M-62.67B-177.49B-180.36B
Gross Margin %63.79%45.94%100%100%100%102.67%100%100%102.3%100.94%100.71%97.87%101.1%101.47%91.43%92.36%91.59%-57.43%-59.81%-27.17%-15.1%-51.83%-67.64%
Gross Profit Growth %--53.45%7.49%9.43%6.52%14.59%-6.61%-16.45%4.15%5.65%5.74%7.56%12.2%18.09%-1.71%6.51%2538.72%17.93%-107.67%99.84%64.69%1.59%-
Operating Expenses623M2.66B41M36M36M41M47M47M825M776M690M627M4.95B4.26B4.1B3.83B3.43B-368.9M-618.9M-561M-303.64B-580.94B-528.82B
OpEx / Revenue %7.74%32.72%0.51%0.48%0.53%0.66%0.84%0.79%11.8%11.41%10.69%9.99%87.61%84.85%87.02%80.57%76.27%-125.43%-179.86%-153.83%-73.17%-169.66%-198.32%
Depreciation & Amortization00000187M00210M107M134M134M-730M-771M-474M00000000
Combined Ratio %20.92%86.78%0.51%0.48%0.53%0.66%0.84%0.79%9.5%10.47%9.98%12.12%86.52%83.38%95.59%88.21%84.68%32%-20.05%-26.65%41.93%-17.82%-30.68%
Operating Income2.5B7.93B7.97B7.42B6.77B1.1B5.53B5.93B728M955M968M884M730M771M474M560M689M200M413.1M461.9M240.97B403.45B348.46B
Operating Margin %31.08%97.72%99.49%99.52%99.47%17.73%99.16%99.21%10.42%14.04%15%14.08%12.92%15.36%10.05%11.79%15.32%68%120.05%126.65%58.07%117.82%130.68%
Operating Income Growth %--0.46%7.46%9.48%513.59%-80.04%-6.66%714.15%-23.77%-1.34%9.5%21.1%-5.32%62.66%-15.36%-18.72%244.5%-51.59%-10.57%-99.81%-40.27%15.78%-
EBITDA937M1.15B1.2B1.15B1.21B1.29B5.53B5.93B938M1.06B1.1B1.02B000823M981M606.4M904.5M937.1M649.39M844.87M348.46B
EBITDA Margin %11.64%14.2%14.98%15.42%17.74%20.73%99.16%99.21%13.42%15.62%17.08%16.21%0%0%0%17.33%21.81%206.19%262.86%256.95%0.16%0.25%130.68%
Interest Expense84M80M76M76M85M94M88M68M62M85M77M74M73M71M85M85M78M70M71.3M72.5M73.23B71.89B57.32B
Non-Operating Income-45M-80M-46M-95M-267M-325M5.53B5.93B27M146M104M134M31M11M-138M-83M-78M-185.9M-297.1M-308.2M240.53B402.78B-9.87B
Pretax Income1.11B1.07B1.12B1.07B1.12B1.33B339M634M639M724M787M565M626M689M537M560M689M315.9M638.9M697.6M356.81B589.54B301.01B
Pretax Margin %13.85%13.17%14.03%14.4%16.49%21.44%6.08%10.61%9.14%10.65%12.2%9%11.08%13.73%11.39%11.79%15.32%107.41%185.67%191.28%85.98%172.17%112.89%
Income Tax236M231M237M221M225M254M25M143M122M247M119M195M220M236M135M240M266M115.9M225.8M235.7M115.84B186.09B-47.45B
Effective Tax Rate %21.17%21.61%21.09%20.6%20.04%19.03%7.37%22.56%19.09%34.12%15.12%34.51%35.14%34.25%25.14%42.86%38.61%36.69%35.34%33.79%32.47%31.57%-15.77%
Net Income879M842M887M852M898M1.34B732M897M530M475M649M352M452M471M488M343M479M195.8M383.2M453.4M206.58B359.86B348.46B
Net Margin %10.92%10.37%11.07%11.43%13.19%21.5%13.12%15.02%7.58%6.98%10.06%5.61%8%9.39%10.35%7.22%10.65%66.58%111.36%124.32%49.78%105.09%130.68%
Net Income Growth %10.01%-5.07%4.11%-5.12%-32.93%82.92%-18.39%69.25%11.58%-26.81%84.38%-22.12%-4.03%-3.48%42.27%-28.39%144.64%-48.9%-15.48%-99.78%-42.59%3.27%-
EPS (Diluted)10.5510.0810.5710.0510.5312.628.219.865.855.297.333.944.975.165.093.334.331.683.113.762691.124962.424827.55
EPS Growth %10.71%-4.64%5.17%-4.56%-16.56%53.72%-16.73%68.55%10.59%-27.83%86.04%-20.72%-3.68%1.38%52.85%-23.09%157.74%-45.98%-17.29%-99.86%-45.77%2.79%-
EPS (Basic)-10.1010.5710.0610.5512.708.259.985.965.417.474.024.975.165.093.394.391.713.263.842736.785013.274879.61
Diluted Shares Outstanding83.3M83.5M83.9M84.8M85.3M85.6M89.2M91M90.6M89.8M88.5M89.4M91M91.2M95.9M102.9M110.5M116.7M123.2M120.5M76.76M72.52M72.18M

Key Metrics

Growth RegimeMixed
ProfitabilityStrong
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Social inflation litigation exposure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Growth Faces Cyclical Headwinds

As reported in recent financial filings, American Financial Group's revenue growth has exhibited significant volatility, fluctuating between a 14.3% expansion in 2024Q1 and a 4.9% contraction in 2025Q1, suggesting that the company is navigating a challenging pricing environment within its core specialty insurance segments.

The inconsistent top-line performance indicates that the firm's decentralized underwriting model may be struggling to maintain consistent volume in a competitive P&C market. Investors should monitor whether the recent revenue deceleration reflects a strategic retreat from unprofitable niches or a broader loss of pricing power in the specialty casualty space.

Underwriting Discipline Drives Profitability Gains

Based on the 2025Q4 combined ratio of 81.6%, the company appears to be maintaining robust underwriting profitability, which suggests that its niche-focused strategy effectively shields the firm from the commodity pricing pressures often seen in broader commercial insurance markets during competitive cycles.

A combined ratio well below the 100% threshold implies that the company is generating substantial underwriting profit, independent of investment returns. This performance warrants further investigation into whether such efficiency is sustainable or if it relies on favorable loss development patterns that may not persist in future periods.

Reserve Quality Remains Critical Variable

According to historical data, the company's reported loss ratios have occasionally dipped into negative territory, such as the -1.3% figure in 2024Q1, which suggests that prior-year reserve releases are playing a material role in smoothing earnings and potentially masking underlying attritional loss trends.

The reliance on reserve adjustments to bolster net income creates uncertainty regarding the true economic profitability of current-year underwriting. Analysts should be cautious, as any shift toward adverse development could quickly erode the reported margins and signal that past pricing assumptions were overly optimistic.

Litigation Risks Threaten Earnings Stability

While the company maintains a strong balance sheet, the rising tide of social inflation and nuclear jury verdicts in the United States poses a significant threat to the Specialty Casualty segment, potentially undermining the long-term sustainability of the firm's current underwriting profit margins.

The decentralized nature of the business units may inadvertently create blind spots regarding the cumulative impact of litigation trends across the portfolio. Investors should monitor whether the company's loss reserves are adequately calibrated to account for the increasing severity of legal settlements, which may not be fully captured in historical loss data.

AFGD — Frequently Asked Questions

Quick answers to the most common questions about buying AFGD stock.

What was American Financial Group, Inc.'s (AFGD) revenue in 2025?

For fiscal year 2025, American Financial Group, Inc. (AFGD) reported total revenue of $8.12B. This represents a 97.0% decline compared to $266.65B in 2003.

Is American Financial Group, Inc. (AFGD) profitable?

American Financial Group, Inc. (AFGD) is profitable, generating $842.0M in net income for the fiscal year ending 2025 with a net profit margin of 10.4%.

What is American Financial Group, Inc.'s operating profit margin?

American Financial Group, Inc. (AFGD) reported an operating income of $7.93B, resulting in an operating profit margin of 97.7%. This margin reflects the operational efficiency of the business before interest and taxes.

What is American Financial Group, Inc.'s gross profit and gross margin?

American Financial Group, Inc. (AFGD) generated $3.73B in gross profit for the year, representing a gross profit margin of 45.9%. This demonstrates the company's core pricing power and production efficiency.